Pharmaceutical company Roche Holding AG (RO.EB) said Thursday it received approval from Swiss regulators for Ocrevus, a treatment for multiple sclerosis, or MS.
Continue Reading Below
"The approval of Ocrevus in Switzerland, the first in Europe, is a significant moment for the Swiss MS community," said Sandra Horning, Roche's chief medical officer and head of global product development.
The treatment is already approved in North and South America, the Middle East, Ukraine and Australia.
Write to Nathan Allen at email@example.com
(END) Dow Jones Newswires
September 28, 2017 01:37 ET (05:37 GMT)